Barclays Maintains an 'Overweight' on Sequenom (SQNM); Lo Publishes Data on T-13/T-18 Detection

Barclays maintains an 'Overweight' on Sequenom (NASDAQ: SQNM), PT $9.

Barclays analyst says, "Following previous publications on non-invasive T-21 detection using sequencing methods, Dennis Lo's group published additional data on T-13/18 detection in the PLoS One journal last night. The study included 392 pregnancies, of which 25 and 37 were identified as T-13 and T-18, respectively. The group employed approaches designed to improve the sensitivity and specificity of T-13 /18 detection, including increasing the number of aligned sequence reads for each sample and correcting the GC-content bias inherent in the sequencing process using bioinformatics methods. This resulted in the sensitivity and specificity of T13 detection improving from 36% and 92.4% respectively, to 100% and 98.9%. The sensitivity and specificity of T18 detection improved from 73% and 97.2% respectively, to 91.9% and 98%."

For more ratings news on Sequenom click here and for the rating history of Sequenom click here.

Shares of Sequenom closed at $7.71 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Citi Reiterates Sell Rating on XPeng (XPEV)
• Lam Research (LRCX) PT Raised to $1,030 at Needham